The Impact of Minimally Invasive Surgery on Treating Patients with Early Cervical Adenocarcinoma

Zhu, Hui; Yan, Yifen; Liu, Ying; Meng, Linghu

doi:10.1080/08941939.2022.2064009

Cited by 5 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this scenario, the ongoing robot-assisted approach to cervical cancer (RACC) randomized clinical trial is trying to assess the oncologic safety of this technique for the surgical treatment of ECC as compared with standard laparotomy, in terms of recurrence-free survival (RFS), OS and quality of life [ 10 ]. Interestingly, a recent analysis has confirmed that, in women with FIGO stage Ib1-IIa2 cervical adenocarcinoma (CA), there were no significant differences between MIS and open surgery in terms of DFS and OS [ 11 , 12 ]. Nevertheless, further analyses of larger series are needed to better investigate the effect of MIS on the survival rate of ECC patients.…”

Section: Minimally Invasive Surgery: Still a Safe Option?mentioning

confidence: 99%

New Advances in Cervical Cancer: From Bench to Bedside

D’Oria

Corrado

Laganà

et al. 2022

IJERPH

View full text Add to dashboard Cite

Cervical cancer is the most common gynecologic malignancy and the fourth most common cancer in women worldwide. Over the last two decades, minimally invasive surgery (MIS) has emerged as the mainstay in the surgical management of early-stage cervical cancer, bringing advantages such as a lower operative morbidity and shorter hospital stay compared to open surgery, while maintaining comparable oncologic outcomes in numerous retrospective studies. Considering oncological patients, it is mandatory to assess the oncological outcomes and safety of this type of surgery. Moreover, there are different future outlooks on cervical cancer therapy, based on immunotherapy, target therapy, and poly-ADP-ribose polymerases (PARP) inhibitors in combination with each other, and in combination with standard chemotherapy and radiotherapy. The goal is to find an approach that is as personalized as possible.

show abstract

Section: Minimally Invasive Surgery: Still a Safe Option?mentioning

confidence: 99%

New Advances in Cervical Cancer: From Bench to Bedside

D’Oria

Corrado

Laganà

et al. 2022

IJERPH

View full text Add to dashboard Cite

show abstract

“…Among the limitations of the present study, we mention the retrospective design, the relatively small number of patients included. Interestingly, a recent analysis has confirmed that, in female with the International Federation of Gynecology and Obstetrics (FIGO) stage Ib1-IIa2 cervical adenocarcinoma (CA), there were no significant differences between LNSRH and open surgery in terms of disease-free survival and overall survival [22,23]. So, further analyses of larger series are needed to better investigate the effect of LNSRH on the survival rate of early cervical cancer (ECC) patients.…”

Section: Discussionmentioning

confidence: 99%

Analysis of the Efficacy of LNSRH Surgery for Early Cervical Cancer Based on T, B, and NK Lymphocytes

He¹,

Ma²,

Zhang³

2023

Clin. Exp. Obstet. Gynecol.

View full text Add to dashboard Cite

Background:The analysis is based on the level of T, B, NK lymphocytes to evaluate the efficacy of laparoscopic nerve-sparing radical hysterectomy (LNSRH) for early cervical cancer. Methods: Selected 30 patients with early cervical cancer who underwent LNSRH surgery in Tianjin Fifth Central Hospital from December 2019 to January 2021 as the cervical cancer group, and 30 healthy female who underwent physical examination in our hospital during the same period were selected as the control group. The expressions of CD4+, CD8+, CD20+, and CD57+ were detected by flow cytometer, female sexual function index (FSFI) and overall assessment scale of cancer treatment function (FACT-G) score were used to evaluate female sexual function and quality of life, and the receiver operating characteristic curve (ROC) was used to analyze the expression predictive value of CD4+, CD8+, CD20+, and CD57+ in LNSRH of early cervical cancer. Results: The expression of CD4+ and CD57+ in the cervical cancer group was lower than that in the healthy group,and the expression of CD8+ and CD20+ was higher than that in the healthy group (p < 0.05). The expression of preoperative CD4+ and CD57+ was higher for postoperative, and the expression of preoperative CD8+ and CD20+ was lower (p < 0.05) for postoperative. The expression of postoperative 1 day CD4+ and CD57+ was higher for at 3 days postoperative, and the expression of postoperative 1 day CD8+ and CD20+ was lower at 3 days postoperative (p < 0.05). CD4+, CD57+ expression was positively correlated with FSFI score, and CD8+, and CD20+ expression was negatively correlated with FSFI score, CD4+, and CD57+ expression was positively correlated with FACT-G score, and CD8+, and CD20+ expression was negatively correlated with FACT-G score (p < 0.05). ROC analysis of CD4+, CD8+, CD20+, CD57+ expression sensitivity was lower than the four-item combination, the specificity was higher than the four-item combination and the results with significant statistical difference (p < 0.05) and the four combined tests have good predictive value for the efficacy of LNSRH for early cervical cancer (p < 0.05). Conclusions: Cervical cancer patients were mainly cellular immunity and performed low expression of CD4+, high expression of CD8+, high expression of CD20+, and low expression of CD57+. T, B, and NK lymphocytes could be used for immunological detection of cervical cancer.

show abstract

Advances in cervical cancer: current insights and future directions

Xu,

Cao,

et al. 2024

Cancer Communications

View full text Add to dashboard Cite

In alignment with the World Health Organization's strategy to eliminate cervical cancer, substantial progress has been made in the treatment of this malignancy. Cervical cancer, largely driven by human papillomavirus (HPV) infection, is considered preventable and manageable because of its well‐established etiology. Advancements in precision screening technologies, such as DNA methylation triage, HPV integration detection, liquid biopsies, and artificial intelligence‐assisted diagnostics, have augmented traditional screening methods such as HPV nucleic acid testing and cytology. Therapeutic strategies aimed at eradicating HPV and reversing precancerous lesions have been refined as pivotal measures for disease prevention. The controversy surrounding surgery for early‐stage cervical cancer revolves around identifying optimal candidates for minimally invasive and conservative procedures without compromising oncological outcomes. Recent clinical trials have yielded promising results for the development of systemic therapies for advanced cervical cancer. Immunotherapies, such as immune checkpoint inhibitors (ICIs), antibody‐drug conjugates (ADCs), and targeted therapy have demonstrated significant effectiveness, marking a substantial advancement in cervical cancer management. Various combination therapies have been validated, and ongoing trials aim to enhance outcomes through the development of novel drugs and optimized combination regimens. The prospect of eradicating cervical cancer as the first malignancy to be eliminated is now within reach. In this review, we provide a comprehensive overview of the latest scientific insights, with a particular focus on precision managements for various stages of cervical disease, and explore future research directions in cervical cancer.

show abstract

The Impact of Minimally Invasive Surgery on Treating Patients with Early Cervical Adenocarcinoma

Cited by 5 publications

References 16 publications

New Advances in Cervical Cancer: From Bench to Bedside

New Advances in Cervical Cancer: From Bench to Bedside

Analysis of the Efficacy of LNSRH Surgery for Early Cervical Cancer Based on T, B, and NK Lymphocytes

Advances in cervical cancer: current insights and future directions

Contact Info

Product

Resources

About